News
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and ...
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...
Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer (PFE) stock is moving higher after beating Wall Street expectations for the second quarter and raising its full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results